[go: up one dir, main page]

CN110225768A - 靶向cxcr7的药物组合物和方法 - Google Patents

靶向cxcr7的药物组合物和方法 Download PDF

Info

Publication number
CN110225768A
CN110225768A CN201880008458.8A CN201880008458A CN110225768A CN 110225768 A CN110225768 A CN 110225768A CN 201880008458 A CN201880008458 A CN 201880008458A CN 110225768 A CN110225768 A CN 110225768A
Authority
CN
China
Prior art keywords
cxcr7
cxcr4
albumen
drug
purposes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880008458.8A
Other languages
English (en)
Inventor
王淼
郝会峰
陈虹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fuwai Hospital of CAMS and PUMC
Original Assignee
Fuwai Hospital of CAMS and PUMC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fuwai Hospital of CAMS and PUMC filed Critical Fuwai Hospital of CAMS and PUMC
Publication of CN110225768A publication Critical patent/CN110225768A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
    • A61L29/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6806—Determination of free amino acids
    • G01N33/6812—Assays for specific amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/606—Coatings

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Food Science & Technology (AREA)
  • Surgery (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明涉及用于治疗心血管疾病的药物组合物和方法。具体而言，本发明涉及靶向CXCR7的治疗对象的血管内皮损伤性疾病或改善对象的心肌梗死后的心脏重塑的方法和药物组合物。

Description

PCT国内申请，说明书已公开。

Claims (27)

  1. PCT国内申请，权利要求书已公开。
CN201880008458.8A 2017-01-26 2018-01-26 靶向cxcr7的药物组合物和方法 Pending CN110225768A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2017100616924 2017-01-26
CN201710061692.4A CN108355133A (zh) 2017-01-26 2017-01-26 靶向cxcr7的药物组合物和方法
PCT/CN2018/074264 WO2018137701A1 (zh) 2017-01-26 2018-01-26 靶向cxcr7的药物组合物和方法

Publications (1)

Publication Number Publication Date
CN110225768A true CN110225768A (zh) 2019-09-10

Family

ID=62979005

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201710061692.4A Pending CN108355133A (zh) 2017-01-26 2017-01-26 靶向cxcr7的药物组合物和方法
CN201880008458.8A Pending CN110225768A (zh) 2017-01-26 2018-01-26 靶向cxcr7的药物组合物和方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201710061692.4A Pending CN108355133A (zh) 2017-01-26 2017-01-26 靶向cxcr7的药物组合物和方法

Country Status (2)

Country Link
CN (2) CN108355133A (zh)
WO (1) WO2018137701A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113811321B (zh) * 2019-05-03 2025-09-30 卢森堡国立健康研究院 新型选择性ackr3调节剂及其用途
WO2024243361A1 (en) * 2023-05-23 2024-11-28 The Regents Of The University Of California Compositions and methods to treat muscle injury and disease

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2716628A1 (en) * 2008-03-24 2009-10-01 Carolus Therapeutics, Inc. Methods and compositions for treating atherosclerosis and related conditions
CN102088993A (zh) * 2008-03-20 2011-06-08 卡罗勒斯治疗公司 炎症的治疗方法
CN103397052A (zh) * 2013-08-15 2013-11-20 温州医科大学 高表达人cxcr7基因的内皮祖细胞及制备方法和应用
CN106065401A (zh) * 2015-04-20 2016-11-02 成都医学院 慢病毒介导cxcr7高表达工程化内皮祖细胞在缺血性疾病中的治疗应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9155723B2 (en) * 2010-06-28 2015-10-13 The General Hospital Corporation Anti-CXCR4 as a sensitizer to cancer therapeutics

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102088993A (zh) * 2008-03-20 2011-06-08 卡罗勒斯治疗公司 炎症的治疗方法
CA2716628A1 (en) * 2008-03-24 2009-10-01 Carolus Therapeutics, Inc. Methods and compositions for treating atherosclerosis and related conditions
CN103397052A (zh) * 2013-08-15 2013-11-20 温州医科大学 高表达人cxcr7基因的内皮祖细胞及制备方法和应用
CN106065401A (zh) * 2015-04-20 2016-11-02 成都医学院 慢病毒介导cxcr7高表达工程化内皮祖细胞在缺血性疾病中的治疗应用

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
XIAOXIAO CAI等: ""Inhibition of Angiogenesis, Fibrosis and Thrombosis by Tetramethylpyrazine: Mechanisms Contributing to the SDF-1/CXCR4 Axis"", 《PLOS ONE》 *
YVONNEDÖRING等: ""The CXCL12/CXCR4 chemokine ligand/receptor axis in cardiovascular disease"", 《FRONTIERS IN PHYSIOLOGY》 *
涂小丽等: ""趋化因子CXCL12/趋化因子受体CXCR7轴与心血管疾病的相关性"", 《重庆医科大学学报》 *
胡旭民等: ""CXCR7在疾病发生和发展中的作用"", 《现代肿瘤医学》 *
金栋等: ""CXCR7 /CXCL12轴对人肝癌细胞增殖能力的影响"", 《宁夏医科大学学报》 *

Also Published As

Publication number Publication date
CN108355133A (zh) 2018-08-03
WO2018137701A1 (zh) 2018-08-02

Similar Documents

Publication Publication Date Title
Pandya et al. Angiogenesis—a new target for future therapy
Oishi et al. AT2 receptor mediates the cardioprotective effects of AT1 receptor antagonist in post-myocardial infarction remodeling
Zhao et al. Angiotensin 1-7 promotes cardiac angiogenesis following infarction
Remuzzi et al. Regression of renal disease by angiotensin II antagonism is caused by regeneration of kidney vasculature
Brenner et al. Short-term inhibition of DPP-4 enhances endothelial regeneration after acute arterial injury via enhanced recruitment of circulating progenitor cells
CN110225768A (zh) 靶向cxcr7的药物组合物和方法
O’Neal et al. Ephrin–Eph signaling as a potential therapeutic target for the treatment of myocardial infarction
Takenaka et al. Midkine prevents ventricular remodeling and improves long-term survival after myocardial infarction
Braga et al. Neointimal hyperplasia
Lu et al. Neovascularization and hematopoietic stem cells
US20110123534A1 (en) Novel compounds for modulating neovascularisation and methods of treatment using these compounds
Singhal et al. Colchicine suppresses atrial fibrillation in failing heart
Fargnoli et al. Cardiac surgical delivery of the sarcoplasmic reticulum calcium ATPase rescues myocytes in ischemic heart failure
US20210238266A1 (en) Compositions and methods for anti-lyst immunomodulation
Okada et al. New insights into the role of basement membrane-derived matricryptins in the heart
Tanaka et al. Effects of bradykinin on cardiovascular remodeling in renovascular hypertensive rats
Pourdjabbar et al. Effects of pre-, peri-, and postmyocardial infarction treatment with losartan in rats: effect of dose on survival, ventricular arrhythmias, function, and remodeling
Cao Monotherapy versus combination therapy of angiogenic and arteriogenic factors for the treatment of ischemic disorders
WO2018130513A1 (en) Use of cd47 antibodies
Li et al. AMD3100 accelerates reendothelialization of neointima in rabbit saccular aneurysm after flow diverter treatment
TWI566780B (zh) 巨噬細胞發炎蛋白－１β（ＭＩＰ－１β）抑制劑用於促進血管新生以改善組織缺血及糖尿病血管病變的用途
Heilmann et al. Improvement of contractility accompanies angiogenesis rather than arteriogenesis in chronic myocardial ischemia
Kingma Myocardial infarction: Perspectives on cardiac regeneration and cardiac remote conditioning interventions to limit cellular injury
Yalcin et al. Impact of previous percutaneous coronary intervention on postoperative outcomes of coronary artery bypass grafting
WO2019025908A1 (en) DEVICE AND METHOD FOR PROMOTING FAST VASCULAR ENDOTHELIAL SUPPORT COVER AND COVERAGE

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190910

WD01 Invention patent application deemed withdrawn after publication